Can text messages help control diabetes in nepal? new trial aims to find out
NCT ID NCT06623006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a text-message based mobile health program can help people with type 2 diabetes in Nepal better manage their condition. 154 adults with type 2 diabetes will be randomly assigned to receive either the text-message program plus standard care, or standard care alone. The main goal is to see if the program leads to better blood sugar control (measured by HbA1c) after 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
text-based mobile health program (behavioral intervention)
What this could lead to
If effective, this low-cost text-message program could improve diabetes self-management and blood sugar control in Nepal and similar low-resource settings.
What could go wrong
This is a relatively small, early-stage trial (154 participants) testing a behavioral intervention, so results may not be generalizable. The effect on HbA1c may be modest or not statistically significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dhulikhel Hospital
Dhulikhel, Bagmati, Nepal